Gilead Sciences/Pharmasset

Target: Pharmasset
Buyer: Gilead Sciences ($GILD)
Price: $11.2 billion
Closed: Jan. 17, 2012
  
Gilead's buyout of Pharmasset was the only deal to close last year that topped out at more than $10 billion. No others came close. There were plenty of critics who thought the price was in fact too rich, but they have gone quiet as Gilead keeps reporting promising results from the hepatitis C drug program at the center of the deal. CEO John Martin said Gilead plans to file an application for the drug this year.

In fact, Gilead has the most advanced program for an all-oral treatment against hep C in the U.S. with its once-daily nucleotide pill. The "nuc" can attack the disease without the nauseating side effects of interferon and doesn't require injections. Analysts see this category of drugs hitting $20 billion in annual sales, which could end up making the Pharmasset deal cheap, particularly if the science spins off other treatments.

Gilead Sciences/Pharmasset
Read more on

Suggested Articles

One year after its landmark Reduce-It CV outcomes trial, Amarin has new data showing its Vascepa may help halt the progress of arterial plaque.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.